Navigation Links
Genelabs Technologies to Present at the BIO CEO & Investor Conference
Date:2/7/2008

REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that its Chief Financial Officer Fred Driscoll will present a company update at the BIO CEO Investor Conference at the Waldorf Astoria Hotel Tuesday, February 12, 2008 at 2:00 pm E.T.

The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at http://www.genelabs.com or through the following URL: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=GNLB&item_id=17523 37 The presentation will also be available for replay after the presentation for a limited time.

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program. We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit http://www.genelabs.com.

Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.

Contact: Frederick W. Driscoll

Chief Financial Officer

Phone: 650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genelabs Technologies, Inc. Announces Resignation of President and CEO
2. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
3. Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions
4. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
5. Guava Technologies Celebrates Tenth Anniversary
6. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
7. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
8. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
11. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture ... the company’s board of directors. This addition continues to strengthen and diversify VIC’s ... Goforth, CEO and Chairman. “He is a highly accomplished business executive with a broad ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... that accelerate pharmaceutical and biotherapeutics development, announces the launch of a new NTA ... biosensor chip enables researchers to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope Foundation ... the first phase of the Allotrope Framework for commercial use. , The Bio-IT ... to “not only elevate the critical role of information technology in modern biomedical ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Heavy-Duty ... orbital shaker models (both analog and digital) for laboratory applications. These shakers ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
Breaking Biology News(10 mins):